zabalafin

Alphyn Biologics, a private dermatology startup, is testing zabalafin hydrogel - a topical investigational botanical drug - in the CLEAR-AD1 Phase 2b vehicle-controlled trial (NCT06855745) for mild-to-moderate atopic dermatitis (AD) [1][2]. The pitch is that one cream hits three things AD skin has wrong at once: Staphylococcus aureus overgrowth, inflammation, and itch [1]. The trial - registered with an enrollment target of 72 but ultimately enrolling ~129 patients across two cohorts per Alphyn's December 2025 announcement [11] - is the asset that matters; everything else is positioning around the readout, which Alphyn has guided for mid-2026 [11].

Novel investigational topical, never approved anywhere. Phase 2b randomized, double-blind, vehicle-controlled, conducted across 12 Australian sites; enrollment completed per Alphyn's December 2025 press release with topline guided for mid-2026 [2][11]. FDA cleared the IND for zabalafin hydrogel in February 2025. No FDA breakthrough therapy, fast track, or orphan designation has been disclosed publicly. Zabalafin is classified by Alphyn as a botanical drug - a multi-component plant-derived active in a hydrogel base - which puts the program under FDA's botanical drug development pathway (21 CFR 312 Subpart I and the FDA Botanical Drug Development Guidance for Industry, 2016) [10]. That pathway allows reliance on prior human-use evidence to support early-phase development, which appears to be how Alphyn moved into Phase 2a without a conventional Phase 1 dose-escalation program. Phase 2a results - including pruritus reduction, IGA improvement, and bacterial clearance signals in AD with secondary bacterial infection - have been published in summary form by Schachner et al. (J Drugs Dermatol 2025) [1]. Alphyn closed a $25M Series B in December 2025 led by QCA Investment Group, on top of a $3.3M Series A in 2022; existing investors include Angel Physicians Fund and Serial Stage Venture Partners [11]. Next regulatory step would be an end-of-Phase-2 meeting with FDA followed by Phase 3 planning, but only if the vIGA endpoint hits cleanly enough to justify the spend. For a private dermatology company with a Series B-stage balance sheet, the realistic path to value is a Phase 2b win that triggers a partnership or licensing deal with a larger dermatology player, not a self-funded march to approval.

Atopic dermatitis is a skin disease with three things going wrong at once. The skin barrier is broken so water escapes and irritants get in. The immune system is stuck in Th2 mode - the branch of immunity that drives allergic inflammation, with cytokines IL-4 and IL-13 doing most of the damage. And the skin is almost universally colonized by S. aureus, the same bacterium that causes staph infections; on AD skin it secretes toxins that drive flares. Most AD drugs attack one of those problems. Dupilumab is a monoclonal antibody that blocks IL-4 and IL-13 signaling [3]. Topical steroids dampen inflammation broadly. JAK inhibitors like ruxolitinib cream block multiple cytokine signals. Zabalafin's claim is a topical that hits Staph colonization, inflammation, and itch in one formulation [1]. As a multi-component botanical, zabalafin does not have a single defined molecular target - the active is a plant-derived extract whose constituents act through multiple pathways, and the company frames the asset around the clinical phenotype it produces rather than a target-engagement mechanism. The mechanism is plausible - combining antimicrobial and anti-inflammatory effects on AD skin has good rationale - but it's not validated by human genetics the way IL-13 blockade is by loss-of-function variants. Validation here will come from the clinical signal versus vehicle, not from target biology. A botanical multi-component active also makes CMC characterization harder than a single small molecule, and FDA's botanical drug pathway exists precisely to handle that complexity [10].

NCT06855745 (CLEAR-AD1): Phase 2b, randomized, double-blind, vehicle-controlled, mild-to-moderate AD, conducted across 12 sites in Australia [2]. The trial registration lists an enrollment target of 72; Alphyn's enrollment-completion announcement reported ~129 patients across two cohorts (Cohort 1 AD without active bacterial infection, Cohort 2 AD with secondary bacterial infection) [11]. Primary endpoint is the validated Investigator Global Assessment (vIGA) clear/almost clear with a ≥2-grade improvement from baseline at Day 113 - the FDA-accepted regulatory endpoint for AD topicals [2]. Registered secondary endpoints are: safety/tolerability via adverse event frequency and severity; absolute change in Eczema Area and Severity Index (EASI) at Days 15, 29, 57, 85, and 113; vIGA response defined as ≥1-point decrease at the specified timepoints; peak pruritus reduction of ≥4 points on the Numerical Rating Scale (NRS); Patient-Oriented Eczema Measure (POEM) response of ≥6-point decrease; and antibacterial efficacy in Cohort 2 [2]. Notably, EASI-75 (75% reduction in EASI from baseline) is NOT a registered endpoint - the secondary EASI measure is absolute change, not the responder-rate threshold familiar from biologics trials. Vehicle control is the right comparator for a Phase 2b topical because it isolates drug effect from the moisturizing effect of the hydrogel base itself, which is non-trivial in AD where emollients alone help. The design choice worth flagging: mild-to-moderate AD is the easier population to recruit and show effect in, but it's also the lower-value commercial segment. Moderate-to-severe AD - where dupilumab and oral JAK inhibitors play and where annual drug spend per patient runs five figures - is the segment with real margin. By staying in mild-to-moderate, Alphyn is competing with topical steroids that cost a few dollars and with newer creams like crisaborole, ruxolitinib cream, tapinarof, and roflumilast cream. The trial also has no active comparator arm, so you'll only learn whether zabalafin beats its own cream base, not whether it beats anything a dermatologist would actually prescribe today.

Only 5% of drugs at this stage are predicted to eventually reach approval. The model starts from the typical success rate for Phase 2 trials in this area - about 30% - then adjusts based on ten specific facts about this trial and its sponsor. The estimate is pulled down mainly by unusually heavy blinding, the sponsor's weak approval track record, limited earlier-phase results, and a randomized trial design. The remaining factors are close to average for this stage, so they don't shift the number much either way.

Efficacy risk is the biggest issue. Vehicle response rates in AD topical trials are not trivial: in the key crisaborole Phase 3 program, the vehicle-arm ISGA success rate (clear/almost clear with ≥2-grade improvement) was 25.4% in AD-301 and 18.0% in AD-302 [5]. The relevant bar for zabalafin is the upper end of that range, not the lower - meaning a placebo-adjusted absolute separation in the high single digits is what crisaborole earned (7.4 points in AD-301, 13.4 points in AD-302) [5]. With ~129 patients across two cohorts, zabalafin needs to convincingly clear the same kind of bar. Mild-to-moderate AD also responds to bathing changes and emollients alone, narrowing the window. Mechanism/CMC risk: a botanical multi-component active is harder to characterize for FDA than a defined small molecule - the botanical drug pathway accommodates this but raises the bar on batch-to-batch consistency and chemistry, manufacturing, and controls (CMC) documentation [10]. There is no published conventional Phase 1 dose-escalation study for zabalafin; the program appears to have relied on the botanical pathway's allowance for prior human-use evidence to enter Phase 2a, with Phase 2a safety/efficacy summarized in Schachner et al. [1][10]. If Alphyn hasn't nailed CMC, Phase 3 gets more expensive and slower. Commercial risk is real even if the trial wins. Mild-to-moderate AD is crowded: generic topical steroids cost pennies, crisaborole (Eucrisa) is approved [6], ruxolitinib cream (Opzelura) is approved [7], tapinarof (Vtama) is approved including an AD indication added in December 2024 [8], and roflumilast cream (Zoryve) is approved for AD as well [9]. To carve out share, zabalafin needs a safety or chronic-use story that beats steroids, ideally without a JAK class warning. Execution risk: Alphyn is private with one asset. The $25M Series B in December 2025 extends runway through the Phase 2b readout and a likely partnering window, but Phase 3 dermatology programs run $50M+ and almost certainly require either a partner or a much larger raise [11].

Worth a glance, not a bookmark. The interesting scientific question is whether Alphyn's AD continuum thesis - that targeting Staph colonization, inflammation, and itch together with a topical produces a clinically meaningful effect - translates into a vIGA response rate that beats vehicle by enough margin to interest a strategic partner. Specific data points to watch at the Day 113 primary timepoint: vIGA clear/almost-clear response rate with at least a high-single-digit to low-double-digit absolute separation from vehicle (the crisaborole bar was 7.4 and 13.4 points in AD-301/AD-302) [5]; absolute EASI change at Day 113 as the lead secondary tell; NRS itch responder rate at the ≥4-point threshold; and the Cohort 2 antibacterial efficacy signal, which is the most differentiated piece of the registered design. Note that EASI-75 (75% reduction in EASI from baseline) - the responder threshold familiar from biologics trials - is NOT a registered endpoint here, so any commentary framing the readout around EASI-75 should be discounted. If the primary and the key secondaries hit, this becomes a partnership story. If the effect is marginal or the vehicle arm responds strongly, it dies quietly. Commercial intelligence on Alphyn beyond the Series B disclosure is limited because the company is private - no SEC filings, no earnings calls, no analyst coverage [11]. Watch ClinicalTrials.gov for status changes, the J Drugs Dermatol paper for framing [1], and dermatology conference abstract lists (AAD, EADV) for the actual readout. Mid-2026 is the guided window. Until then, this is a small private-company shot on goal in a segment where the more important narrative is the JAK cream competitive market and the next wave of IL-13 / IL-31 biologics for moderate-to-severe disease.